Switch theme
Sign up to access all valuation multiples
Stille AB manufactures and distributes medical devices. Its products include surgical equipment such as Surgical Scissors, Forceps, Curettes, Raspatories, Elevators, c-arm tables and instrument care education, among others.
1841
59
LTM Revenue $59.5M
LTM EBITDA $11.4M
$177M
Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.
Stille has a last 12-month revenue of $59.5M and a last 12-month EBITDA of $11.4M.
In the most recent fiscal year, Stille achieved revenue of $58.7M and an EBITDA of $8.7M.
Stille expects next 12-month revenue of XXX and NTM EBITDA of XXX
See Stille valuation multiples based on analyst estimates| FY 2023 | FY 2024 | FY 2025 | LTM | NTM | |
|---|---|---|---|---|---|
| Revenue | $30.4M | $58.7M | XXX | XXX | XXX |
| Gross Profit | $11.5M | $13.6M | XXX | XXX | XXX |
| Gross Margin | 38% | 23% | XXX | XXX | XXX |
| EBITDA | $5.8M | $8.7M | XXX | XXX | XXX |
| EBITDA Margin | 19% | 15% | XXX | XXX | XXX |
| Net Profit | $2.8M | $2.7M | XXX | XXX | XXX |
| Net Margin | 9% | 5% | XXX | XXX | XXX |
| Net Debt | $0.9M | n/a | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
As of May 13, 2025, Stille's stock price is SEK 211 (or $22).
Stille has current market cap of SEK 1.9B (or $195M), and EV of SEK 1.7B (or $177M).
See Stille trading valuation data| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $177M | $195M | XXX | XXX | XXX | XXX | $0.75 |
Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more
Start Free TrialAs of May 13, 2025, Stille has market cap of $195M and EV of $177M.
Stille's trades at 3.0x LTM EV/Revenue multiple, and 15.5x LTM EBITDA.
Analysts estimate Stille's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
See valuation multiples for Stille and 10K+ public comps| FY 2024 | FY 2025E | FY 2026E | FY 2027E | |
|---|---|---|---|---|
| EV | $177M | XXX | XXX | XXX |
| EV/Revenue | 3.0x | XXX | XXX | XXX |
| EV/EBITDA | 20.3x | XXX | XXX | XXX |
| P/E | 32.6x | XXX | XXX | XXX |
| P/E/Growth | 0.8x | XXX | XXX | XXX |
| EV/FCF | 29.0x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.
Start Free TrialStille's NTM/LTM revenue growth is 6%
Stille's revenue per employee for the last fiscal year averaged $1.0M, while opex per employee averaged n/a for the same period.
Over next 12 months, Stille's ratio of sales and marketing spend to revenue is estimated to be XXX , while its R&D spend to revenue to be XXX .
Analysts estimate Stille's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
See operational valuation multiples for Stille and other 10K+ public comps| FY 2024 | NTM | FY 2025E | FY 2026E | FY 2027E | |
|---|---|---|---|---|---|
| Revenue Growth | 93% | XXX | XXX | XXX | XXX |
| EBITDA Margin | N/A | XXX | XXX | XXX | XXX |
| EBITDA Growth | 51% | XXX | XXX | XXX | XXX |
| Rule of 40 (SaaS-only) | 0% | XXX | XXX | XXX | XXX |
| Revenue per Employee | $1.0M | XXX | XXX | XXX | XXX |
| Opex per Employee | n/a | XXX | XXX | XXX | XXX |
| S&M Expenses to Revenue | 0% | XXX | XXX | XXX | XXX |
| G&A Expenses to Revenue | n/a | XXX | XXX | XXX | XXX |
| R&D Expenses to Revenue | n/a | XXX | XXX | XXX | XXX |
| Opex to Revenue | 0% | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| 2025E | 2026E | 2027E | 2025E | 2026E | 2027E | |
| Ansell | XXX | XXX | XXX | XXX | XXX | XXX |
| Polymed | XXX | XXX | XXX | XXX | XXX | XXX |
| Farmaceutica Remedia | XXX | XXX | XXX | XXX | XXX | XXX |
| Etropal | XXX | XXX | XXX | XXX | XXX | XXX |
| Sopharma | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Stille acquired XXX companies to date.
Last acquisition by Stille was XXXXXXXX, XXXXX XXXXX XXXXXX . Stille acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX ).
See M&A valuation multiples| Acquired Company | EV | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.
Start Free Trial| When was Stille founded? | Stille was founded in 1841. |
| Where is Stille headquartered? | Stille is headquartered in Sweden. |
| How many employees does Stille have? | As of today, Stille has 59 employees. |
| Is Stille publicy listed? | Yes, Stille is a public company listed on STO. |
| What is the stock symbol of Stille? | Stille trades under STIL ticker. |
| When did Stille go public? | Stille went public in 2005. |
| Who are competitors of Stille? | Similar companies to Stille include e.g. Ansell, Polymed, Farmaceutica Remedia, Etropal. |
| What is the current market cap of Stille? | Stille's current market cap is $195M |
| What is the current revenue of Stille? | Stille's last 12-month revenue is $59.5M. |
| What is the current EBITDA of Stille? | Stille's last 12-month EBITDA is $11.4M. |
| What is the current EV/Revenue multiple of Stille? | Current revenue multiple of Stille is 3.0x. |
| What is the current EV/EBITDA multiple of Stille? | Current EBITDA multiple of Stille is 15.5x. |
| What is the current revenue growth of Stille? | Stille revenue growth between 2023 and 2024 was 93%. |
| Is Stille profitable? | Yes, Stille is EBITDA-positive (as of the last 12 months). |
Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.
